CD40-activated B cells can be generated in high number and purity in cancer patients: analysis of immunogenicity and homing potential

Cellular adjuvants such as dendritic cells (DC) are in the focus of tumour immunotherapy. In DC-vaccine trials, induction of tumour antigen-specific immunity is observed frequently and well-documented clinical responses have been reported. However, the overall response rate is less than 3%, therefor...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Kondo, E, Gryschok, L, Klein-Gonzalez, N, Rademacher, S, Weihrauch, M R, Liebig, T, Shimabukuro-Vornhagen, A, Kochanek, M, Draube, A, von Bergwelt-Baildon, M S
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Blackwell Science Inc 2009
Gaiak:
Basic Studies
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC2675256/
https://ncbi.nlm.nih.gov/pubmed/19040609
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1365-2249.2008.03820.x
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak